SE8803087L - Ett nytt saett foer behandling av erektil dysfunktion - Google Patents

Ett nytt saett foer behandling av erektil dysfunktion

Info

Publication number
SE8803087L
SE8803087L SE8803087A SE8803087A SE8803087L SE 8803087 L SE8803087 L SE 8803087L SE 8803087 A SE8803087 A SE 8803087A SE 8803087 A SE8803087 A SE 8803087A SE 8803087 L SE8803087 L SE 8803087L
Authority
SE
Sweden
Prior art keywords
dysfunction
erect
treatment
new set
optionally
Prior art date
Application number
SE8803087A
Other languages
English (en)
Other versions
SE8803087D0 (sv
SE463851B (sv
Inventor
N G Kock
Original Assignee
Amsu Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE8803087(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amsu Ltd filed Critical Amsu Ltd
Priority to SE8803087A priority Critical patent/SE463851B/sv
Publication of SE8803087D0 publication Critical patent/SE8803087D0/sv
Priority to IE268089A priority patent/IE62587B1/en
Priority to NZ230400A priority patent/NZ230400A/xx
Priority to ES89850282T priority patent/ES2055677T5/es
Priority to EP89850282A priority patent/EP0357581B2/en
Priority to ZA896681A priority patent/ZA896681B/xx
Priority to JP1509519A priority patent/JPH0791199B2/ja
Priority to DE68907909T priority patent/DE68907909T3/de
Priority to CA000610172A priority patent/CA1335346C/en
Priority to EP89909891A priority patent/EP0432199B2/en
Priority to AU41994/89A priority patent/AU638414B2/en
Priority to PCT/SE1989/000462 priority patent/WO1990002545A1/en
Priority to AT89909891T priority patent/ATE91886T1/de
Publication of SE8803087L publication Critical patent/SE8803087L/sv
Publication of SE463851B publication Critical patent/SE463851B/sv
Priority to FI910976A priority patent/FI102454B1/sv
Priority to NO910828A priority patent/NO301046B1/no
Priority to DK199100364A priority patent/DK175560B1/da
Priority to GR90300093T priority patent/GR900300093T1/el
Priority to US08/481,609 priority patent/US5942512A/en
Priority to US08/485,041 priority patent/US5886039A/en
Priority to US08/484,546 priority patent/US5843961A/en
Priority to US08/478,982 priority patent/US5849803A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8803087A 1988-09-02 1988-09-02 Komposition foer behandling av erektil dysfunktion via uretra SE463851B (sv)

Priority Applications (21)

Application Number Priority Date Filing Date Title
SE8803087A SE463851B (sv) 1988-09-02 1988-09-02 Komposition foer behandling av erektil dysfunktion via uretra
IE268089A IE62587B1 (en) 1988-09-02 1989-08-21 Composition for the treatment of erectile dysfunction
NZ230400A NZ230400A (en) 1988-09-02 1989-08-22 Phentolamine and hydrophilic vehicle for use in treating erectile dysfunction
ES89850282T ES2055677T5 (es) 1988-09-02 1989-08-31 Composicion para el tratamiento de la disfuncion erectil.
EP89850282A EP0357581B2 (en) 1988-09-02 1989-08-31 Composition for the treatment of erectile dysfunction
ZA896681A ZA896681B (en) 1988-09-02 1989-08-31 A composition for the treatment of erectile dysfunction
AT89909891T ATE91886T1 (de) 1988-09-02 1989-09-01 Praeparat zur behandlung von erektionsstoerungen.
DE68907909T DE68907909T3 (de) 1988-09-02 1989-09-01 Präparat zur behandlung von erektionsstörungen.
EP89909891A EP0432199B2 (en) 1988-09-02 1989-09-01 Composition for the treatment of erectile dysfunction
PCT/SE1989/000462 WO1990002545A1 (en) 1988-09-02 1989-09-01 Composition for the treatment of erectile dysfunction
CA000610172A CA1335346C (en) 1988-09-02 1989-09-01 Method of treating erectile dysfunction
JP1509519A JPH0791199B2 (ja) 1988-09-02 1989-09-01 勃起機能障害の治療用組成物
AU41994/89A AU638414B2 (en) 1988-09-02 1989-09-01 Composition for the treatment of erectile dysfunction
FI910976A FI102454B1 (sv) 1988-09-02 1991-02-27 Förfarande för framställning av en komposition för behandling av erektil funktionsstörning
DK199100364A DK175560B1 (da) 1988-09-02 1991-03-01 Præparat til behandling af erektiv dysfunktion
NO910828A NO301046B1 (no) 1988-09-02 1991-03-01 Fremgangsmåte for fremstilling av preparat for behandling av erektil funksjonssvikt
GR90300093T GR900300093T1 (en) 1988-09-02 1991-09-27 Composition for the treatment of erectile dysfunction
US08/478,982 US5849803A (en) 1988-09-02 1995-06-07 Method of treating erectile dysfunction with nitroglycerine
US08/481,609 US5942512A (en) 1988-09-02 1995-06-07 Method and composition for treating erectile dysfunction
US08/485,041 US5886039A (en) 1988-09-02 1995-06-07 Method and composition for treating erectile dysfunction
US08/484,546 US5843961A (en) 1988-09-02 1995-06-07 Method and composition for treating erectile dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803087A SE463851B (sv) 1988-09-02 1988-09-02 Komposition foer behandling av erektil dysfunktion via uretra

Publications (3)

Publication Number Publication Date
SE8803087D0 SE8803087D0 (sv) 1988-09-02
SE8803087L true SE8803087L (sv) 1990-03-03
SE463851B SE463851B (sv) 1991-02-04

Family

ID=20373202

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8803087A SE463851B (sv) 1988-09-02 1988-09-02 Komposition foer behandling av erektil dysfunktion via uretra

Country Status (16)

Country Link
US (4) US5849803A (sv)
EP (2) EP0357581B2 (sv)
JP (1) JPH0791199B2 (sv)
AU (1) AU638414B2 (sv)
CA (1) CA1335346C (sv)
DE (1) DE68907909T3 (sv)
DK (1) DK175560B1 (sv)
ES (1) ES2055677T5 (sv)
FI (1) FI102454B1 (sv)
GR (1) GR900300093T1 (sv)
IE (1) IE62587B1 (sv)
NO (1) NO301046B1 (sv)
NZ (1) NZ230400A (sv)
SE (1) SE463851B (sv)
WO (1) WO1990002545A1 (sv)
ZA (1) ZA896681B (sv)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
NZ237899A (en) * 1990-04-25 1997-03-24 Vivus Inc Substituted For Alza An apparatus comprising a shaft and a therapeutic composition; suitable to treat erectile dysfunction by insertion in the urethra
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5981593A (en) * 1991-07-03 1999-11-09 Scott; Nathan Earl Prostaglandin E2 treatment of impotence
US6291528B1 (en) 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
US5503973A (en) * 1992-05-29 1996-04-02 The Regents Of The University Of California Method for inhibition of viral morphogenesis
US20030181355A1 (en) * 1992-05-29 2003-09-25 Glenn Jeffrey S. Method for inhibition of viral infection
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5910316A (en) * 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
BR9607365A (pt) * 1995-03-14 1997-12-30 Vivus Inc Processo e kit para prevenir disfunção de ereção
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5718917A (en) * 1995-12-15 1998-02-17 Harvard Scientific Corporation PGE-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
GB9608408D0 (en) * 1996-04-23 1996-06-26 Adams Michael A Treatment of erectile dysfunction
IT1292377B1 (it) 1997-06-19 1999-02-08 Nicox Sa Composizioni farmaceutiche a base di prostaglandine
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
AU742787B2 (en) 1997-07-09 2002-01-10 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6200288B1 (en) 1997-08-26 2001-03-13 Queen's University At Kingston Everting toroid device for insertion into a body cavity
US5954688A (en) * 1997-08-26 1999-09-21 Queen's University At Kingston Everting toroid device for delivering a drug into a body cavity
US5925629A (en) * 1997-10-28 1999-07-20 Vivus, Incorporated Transurethral administration of androgenic agents for the treatment of erectile dysfunction
US5919474A (en) * 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1059926A2 (en) * 1997-12-18 2000-12-20 SCOTT, Nathan Earl PROSTAGLANDIN E 2?/F 2$g(a)? COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
AU3198899A (en) 1998-03-20 1999-10-11 Rockefeller University, The Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6132757A (en) 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
CA2353613A1 (en) * 1998-12-02 2000-06-08 Shigeharu Suzuki Preparations for intraurethral administration
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
WO2000066114A1 (en) 1999-04-30 2000-11-09 Lilly Icos Llc Treatment of female arousal disorder
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
US7105571B2 (en) 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002102385A1 (en) * 2001-06-14 2002-12-27 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
US20040142929A1 (en) * 2001-07-06 2004-07-22 Ramon Merce-Vidal Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence
CN1203055C (zh) 2001-09-26 2005-05-25 朱德煦 治疗或预防细菌感染的方法和组合物
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
WO2003075860A2 (en) * 2002-03-08 2003-09-18 Abgent, Inc. Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof
AU2003218600C1 (en) * 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
KR20040043996A (ko) * 2002-11-20 2004-05-27 조나겐, 아이엔씨. 남성 발기부전치료를 위한 개선된 조성물
US7517887B2 (en) * 2003-04-09 2009-04-14 General Atomics Reversible inhibitors of S-adenosyl-L-homocysteine hydrolase and uses thereof
US7868011B2 (en) * 2003-04-09 2011-01-11 General Atomics Use of reversible inhibitors of S-adenosyl-L-homocysteine hydrolase for treating lupus
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
CN1869002A (zh) * 2005-05-27 2006-11-29 中国科学院上海药物研究所 一类非甾体雄激素受体调节剂、其制备方法和用途
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
CN102917699A (zh) 2009-10-13 2013-02-06 密执安大学评议会 树枝状聚合物组合物和合成方法
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
EP3858979A1 (en) 2010-06-13 2021-08-04 Institute of Biophysics Chinese Academy of Sciences Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
EP2891712A4 (en) 2012-07-23 2016-04-06 Inst Biophysics Cn Acad Sci METHOD OF INDUCING THE DIFFERENTIATION OF PLURIPOTENT STEM CELLS IN VITRICULAR MYOCYTES IN VITRO
EP2903632A4 (en) 2012-10-08 2016-07-13 Zensun Shanghai Science And Technology Ltd COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE IN DIABETES PATIENTS
CN105611955A (zh) 2013-05-22 2016-05-25 上海泽生科技开发有限公司 缓释纽兰格林治疗心力衰竭
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
FR2509175B1 (fr) * 1981-03-06 1987-01-16 Toyo Jozo Kk Preparation therapeutique ayant d'excellentes proprietes d'absorption
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
EP0149254A3 (en) * 1983-12-29 1987-01-28 The Research Foundation Of State University Of New York Fungicidal polypeptide compositions containing l-histidine
DE3637157A1 (de) * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
EP0266968A3 (en) * 1986-11-03 1988-08-24 Gérard G. Cohen Gelled ointment of vasodilating agent
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
DE3943519A1 (de) * 1989-04-27 1991-01-17 Stief Georg Arzneimittel zur behandlung erektiler dysfunktionen
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence

Also Published As

Publication number Publication date
IE62587B1 (en) 1995-02-08
JPH0791199B2 (ja) 1995-10-04
AU4199489A (en) 1990-04-02
FI102454B (sv) 1998-12-15
NO910828D0 (no) 1991-03-01
US5843961A (en) 1998-12-01
EP0432199B1 (en) 1993-07-28
SE8803087D0 (sv) 1988-09-02
US5942512A (en) 1999-08-24
DE68907909T3 (de) 2004-02-26
ES2055677T1 (es) 1994-09-01
DK175560B1 (da) 2004-12-06
EP0357581B1 (en) 1993-07-28
FI910976A0 (fi) 1991-02-27
US5849803A (en) 1998-12-15
EP0357581B2 (en) 1998-09-16
SE463851B (sv) 1991-02-04
NZ230400A (en) 1992-01-29
AU638414B2 (en) 1993-07-01
CA1335346C (en) 1995-04-25
GR900300093T1 (en) 1991-09-27
ES2055677T5 (es) 1998-11-16
DK36491A (da) 1991-03-01
NO301046B1 (no) 1997-09-08
DK36491D0 (da) 1991-03-01
NO910828L (no) 1991-04-30
WO1990002545A1 (en) 1990-03-22
ZA896681B (en) 1990-06-27
US5886039A (en) 1999-03-23
JPH04501707A (ja) 1992-03-26
FI102454B1 (sv) 1998-12-15
DE68907909T2 (de) 1993-12-23
ES2055677T3 (es) 1994-11-01
EP0432199B2 (en) 2003-07-30
IE892680L (en) 1990-03-02
EP0432199A1 (en) 1991-06-19
DE68907909D1 (de) 1993-09-02
EP0357581A1 (en) 1990-03-07

Similar Documents

Publication Publication Date Title
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
LV12452A (lv) Aktivas vielas vaginala ievadisanas sistema
CA2055493A1 (en) Antineoplastic solution and method for treating neoplasms
DE69130529T2 (de) Behandlung von erektionversagen
SE8803486D0 (sv) Dosage form for treating cardiovascular diseases
ATE110578T1 (de) Von hydrogel angetriebene verabreichungsvorrichtung.
DE19675046I2 (de) Pharmazeutische Verbindungen
ATE290836T1 (de) Intravaginal-ringe mit einsetzbarem medikamentenenthaltenden kern
PT637933E (pt) Metodo para tratamento de orgaos e tecidos
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
ES2095578T3 (es) Composicion para el tratamiento de mastitis y metritis.
DE59506374D1 (de) Neue 3-Phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonan-Verbindungen enthaltende Arzneimittel
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
ES2129401T3 (es) Uso de un compuesto terapeutico para el tratamiento de bronquitis.
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2054652T3 (es) Composicion farmaceutica acuosa.
EP0539516A4 (sv)
AU5903690A (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e) azepine-6, 11-dione and derivatives as drugs for use in the treatment of urinary incontinence
ES2113870T3 (es) Utilizacion de n,n'-bis 3-(etilamino)propil-1,7-heptanodiamina y un agente citotoxico.
KR927003530A (ko) 이온삼투요법용 제약 제제의 제조에 있어서의 국소 마취제의 용도
KR930700109A (ko) 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘
RU97108766A (ru) Способ лечения токсико-септических состояний у новорожденных детей

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8803087-9

Format of ref document f/p: F

NUG Patent has lapsed